Evidence map›Paper›PMID 29426300›Full record

Trial reportBMC nephrology2018

Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.

Bhupesh Panwar, Diane McCann, Gordana Olbina, Mark Westerman, Orlando M Gutiérrez

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01988116 (Vitamin D Replacement in Chronic Kidney Disease and Its Effects on Iron Homeostasis, Serum Hepcidin, and Hemojuvelin Levels.), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01988116 early_phase1completednot on this map

Vitamin D Replacement in Chronic Kidney Disease and Its Effects on Iron Homeostasis, Serum Hepcidin, and Hemojuvelin Levels.

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2013 to 2015Enrolled40ConditionsChronic Kidney Disease, Anemia of Chronic DiseaseArmsOral Calcitriol 0.5 mcg once daily for 6 weeks, Placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. The Influence of Inflammation on Anemia in CKD Patients.International journal of molecular sciences · 2020
    Review
  9. Review
  10. Article
  11. Hepcidin Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2018
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bhupesh PanwarDepartments of Medicine, University of Alabama at Birmingham, ZRB 522, 1720 2nd AVE S, Birmingham, AL, 35294-0006, USA. bpanwar@uabmc.edu.
Diane McCannIntrinsic LifeSciences, La Jolla, CA, USA.
Gordana OlbinaIntrinsic LifeSciences, La Jolla, CA, USA.
Mark WestermanIntrinsic LifeSciences, La Jolla, CA, USA.
Orlando M GutiérrezDepartments of Medicine, University of Alabama at Birmingham, ZRB 522, 1720 2nd AVE S, Birmingham, AL, 35294-0006, USA.

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2000 to 2026
$31.9M
Impact of disordered mineral metabolism on stroke and cognitive impairmentR01NS080850 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M · 2012 to 2016
$1.2M
NIDDK NIH HHS P30 DK056336NIH HHS R01NS080850NINDS NIH HHS R01 NS080850
6 · The paper itself

Abstract

backgroundAnemia is highly prevalent in chronic kidney disease (CKD). Elevated hepcidin concentrations are an important mediator of disordered iron metabolism, a key mechanism underlying anemia of CKD. Vitamin D was recently shown to reduce serum hepcidin concentrations in healthy individuals. We examined whether treatment with calcitriol reduces serum hepcidin in individuals with CKD.

methodsA total of 40 participants with stage 3 or 4 CKD (eGFR 15-60 ml/min/1.73m

resultsThere were no significant differences in the baseline characteristics between the placebo and calcitriol arms. Over 6 weeks of follow-up there were no significant differences in the change in serum hepcidin, iron parameters, or hemoglobin between the two groups. Serum calcium and phosphorus significantly increased and PTH significantly decreased after 6 weeks in calcitriol group whereas these analytes did not change in the placebo group.

conclusionCalcitriol did not reduce serum hepcidin concentrations among individuals with mild to moderate CKD. Future studies are needed to assess if nutritional forms of vitamin D affect hepcidin concentrations in CKD.

trial registrationClinicalTrials.gov Identifier: NCT01988116 . Registered: November 4, 2013.

Indexed as

AgedBiomarkersCalcitriolCalcium Channel AgonistsDouble-Blind MethodFemaleHepcidinsHumansMaleMiddle AgedRenal Insufficiency, ChronicTreatment OutcomeBiomarkersCalcitriolCalcium Channel AgonistsHepcidinsAnemia of CKDCalcitriolChronic kidney diseaseHepcidinVitamin D

Identifiers

PMID29426300
PMCPMC5807766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.